- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Febuxostat demonstrates efficacy and renal safety in patients with gout and CKD
![Febuxostat demonstrates efficacy and renal safety in patients with gout and CKD Febuxostat demonstrates efficacy and renal safety in patients with gout and CKD](https://medicaldialogues.in/h-upload/2022/11/16/750x450_191160-tablets.webp)
Peiyu Zhang et al conducted a study to explore the efficacy and renal safety of febuxostat in gout and stage 2-4 chronic kidney disease (CKD) and factors that correlated with target serum urate (SU).The article has been published in Rheumatology therapy journal.
A single-center retrospective study including male patients with gout and CKD was conducted. SU, the rate of SU < 360 umol/L (RAT), and renal safety were analyzed in subjects who received febuxostat over 44 weeks.
Key findings of the study were:
• 102 patients (stage 2 CKD: n = 27; stage 3 CKD: n = 70; stage 4 CKD: n = 5) were enrolled.
• The SU level reduced significantly over 44 weeks (600.76 ± 95.42 versus 405.52 ± 111.93 umol/ L; P <0.05), and RAT increased to 39.20%.
• The overall estimated glomerular filtration rate (eGFR) level improved over 44 weeks (52.05 ± 11.68 versus 55.46 ± 14.49 mL/min/ 1.73 cm2, p <0.05).
• An obvious improvement of eGFR was observed in stage 3 CKD, in patients with <= 1 risk factor (hypertension, diabetic mellitus, hyperlipidemia, or usage of non-steroidal anti-inflammatory drugs), and in patients with terminal SU <360 umol/L (p <0.05).
• Logistic regression analysis indicated that baseline SU level and body weight were correlated with RAT.
• Patients with SU<600 umol/L and body weight <=70 kg reached higher RAT (56.7%).
The authors concluded that – "In patients with gout and CKD, urate lowering treatment with febuxostat significantly reduces SU levels and could improve renal function. Significant improvement in renal function was achieved in patients with stage 3 CKD, without hypertension, diabetic mellitus, hyperlipidemia, or usage of NSAIDs. A ''treat to target'' therapy with febuxostat could obviously improve renal function. Besides, patients with baseline SU <600 umol/L and body weight B 70 kg were more likely to achieve target SU.
Further reading:
Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
Peiyu Zhang, Mo Chen et al
Rheumatology Therapy (2022) 9:1421–1434
https://doi.org/10.1007/s40744-022-00480-7
MBBS, Dip. Ortho, DNB ortho, MNAMS
Dr Supreeth D R (MBBS, Dip. Ortho, DNB ortho, MNAMS) is a practicing orthopedician with interest in medical research and publishing articles. He completed MBBS from mysore medical college, dip ortho from Trivandrum medical college and sec. DNB from Manipal Hospital, Bengaluru. He has expirence of 7years in the field of orthopedics. He has presented scientific papers & posters in various state, national and international conferences. His interest in writing articles lead the way to join medical dialogues. He can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751